Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?

SIMPLE SUMMARY: In patients with progressive metastatic radioiodine-refractory differentiated thyroid cancer, tyrosine kinase inhibitor (TKI) therapy with lenvatinib improves progression-free survival. Early identification of patients with therapeutic responses to the TKI therapy is clinically relev...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendl, Gundula, Schweighofer-Zwink, Gregor, Sorko, Stefan, Gallowitsch, Hans-Jürgen, Hitzl, Wolfgang, Reisinger, Diana, Pirich, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029268/
https://www.ncbi.nlm.nih.gov/pubmed/35454777
http://dx.doi.org/10.3390/cancers14081868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029268/
https://www.ncbi.nlm.nih.gov/pubmed/35454777
http://dx.doi.org/10.3390/cancers14081868

Ejemplares similares